---

Figure INF-1: AIDS incidence by year of diagnosis adjusted for reporting delays – Part (i) Incidence among injecting drug users by country, 1995 to 2004

Figure INF-1: AIDS incidence by year of diagnosis adjusted for reporting delays – Part (ii) Incidence by transmission group – summary for EU countries, 1995 to 2004

Figure INF-2: HIV infections newly diagnosed in injecting drug users by year of report 1995 to 2004, cases per million population – Part (i) EU countries, candidate countries and Norway

Figure INF-2: HIV infections newly diagnosed in injecting drug users by year of report 1995 to 2004, cases per million population – Part (ii) Estonia, Latvia, Lithuania, Portugal, Russian Federation and Ukraine

Figure INF-2: HIV infections newly diagnosed in injecting drug users by year of report 1995 to 2004, cases per million population – Part (iii) EU, candidate countries and Norway, excluding Estonia, Latvia, Lithuania and Portugal

Figure INF-3: HIV prevalence among injecting drug users – studies with national and sub-national coverage – Part (i) All injecting drug users, 2003 to 2004

Figure INF-3: HIV prevalence among injecting drug users – studies with national and sub-national coverage – Part (ii) Young injecting drug users (under age 25), 2003 to 2004

Figure INF-3: HIV prevalence among injecting drug users – studies with national and sub-national coverage – Part (iii) All injecting drug users by gender, age, years of injecting and primary drug (where data available), 2000 to 2004

Figure INF-3: HIV prevalence among injecting drug users – studies with national and sub-national coverage – Part (iv) All injecting drug users – Map of EU, 2003 to 2004

Figure INF-3: HIV prevalence among injecting drug users – studies with national and sub-national coverage – Part (v) All injecting drug users, by gender (where data available), 2003 to 2004

Figure INF-4: Trends in HIV prevalence among injecting drug users estimated from national and sub-national samples, 1995 to 2004 – Part (i) All injecting drug users

Figure INF-4: Trends in HIV prevalence among injecting drug users estimated from national and sub-national samples, 1995 to 2004 – Part (ii) Young injecting drug users (under age 25)

Figure INF-4: Trends in HIV prevalence among injecting drug users estimated from national and sub-national samples, 1995 to 2004 – Part (iii) New injecting drug users (injecting less than 2 years)

Figure INF-5: Estimated HIV prevalence among injecting drug users selected country-specific studies – Part (i) Italy – prevalence among users in drug treatment and prisons, by region, 2000 to 2004

Figure INF-5: Estimated HIV prevalence among injecting drug users – selected country-specific studies – Part (ii) France – prevalence among users in 12 cities by gender, age and opioids use, 2001 to 2003

Figure INF-5: Estimated HIV prevalence among injecting drug users – selected country-specific studies – Part (iii) Luxembourg – prevalence among users in contact with drug services, by gender and age, 1996 to 2004

Figure INF-5: Estimated HIV prevalence among injecting drug users – selected country-specific studies – Part (iv) UK (England and Wales) – prevalence among users in contact with drug services, by gender, age and injecting history

Figure INF-5: Estimated HIV prevalence among injecting drug users – selected country-specific studies – Part (v) Austria – prevalence among drug-related deaths (injecting drug users) by gender, age and opioid-relatedness, 1995 to 2004

Figure INF-5: Estimated HIV prevalence among injecting drug users – selected country-specific studies – Part (vii) Spain – prevalence among injecting drug users in drug treatment, by gender, age, injecting history, opioids use and first treatment demand, 1996 to 2002

Figure INF-6: Estimated HCV antibody prevalence among injecting drug users – studies with national and sub-national coverage – Part (i) All injecting drug users, 2003 to 2004

Figure INF-6: Estimated HCV antibody prevalence among injecting drug users – studies with national and sub-national coverage – Part (ii) Young injecting drug users (under age 25), 2003 to 2004

Figure INF-6: Estimated HCV antibody prevalence among injecting drug users – studies with national and sub-national coverage – Part (iii) New injecting drug users (injecting less than 2 years), 2003 to 2004

Figure INF-6: Estimated HCV antibody prevalence among injecting drug users – studies with national and sub-national coverage – Part (iv) All injecting drug users – map of EU, 2003 to 2004

Figure INF-6: Estimated HCV antibody prevalence among injecting drug users – studies with national and sub-national coverage – Part (v) All injecting drug users by gender, age, years of injecting and primary drug (where data is available)

Figure INF-7: Trends in HCV antibody prevalence estimated from national and sub-national samples of injecting drug users 1995 to 2004, in EU countries where data are available – Part (i) All injecting drug users

Figure INF-7: Trends in HCV antibody prevalence estimated from national and sub-national samples of injecting drug users 1995 to 2004, in EU countries where data are available – Part (ii) Young injecting drug users (under age 25)

Figure INF-7: Trends in HCV antibody prevalence estimated from national and sub-national samples of injecting drug users 1995 to 2004, in EU countries where data are available – Part (iii) New injecting drug users (injecting less than 2 years)

Figure INF-8: Notified cases of hepatitis C related to injecting drug use, EU countries where data are available – Part (i) Proportion injecting drug users among all cases with risk factor information, 2000 to 2004

Figure INF-8: Notified cases of hepatitis C related to injecting drug use, EU countries where data are available – Part (ii) Indexed trend in numbers of injecting drug users, 1995 to 2004

Figure INF-9: Prevalence of HCV current infection and HCV genotypes among injecting drug users, where data available – Part (i) Percentage RNA positive and percentage HCV antibody positive injecting drug users

Figure INF-9: Prevalence of HCV current infection and HCV genotypes among injecting drug users, where data available – Part (ii) Percentage RNA positive and HCV antibody positive in samples of injecting drug users

Figure INF-9: Prevalence of HCV current infection and HCV genotypes among injecting drug users, where data available – Part (iii) Percentage distribution of HCV genotypes (G1 to G4) in samples of injecting drug users

Figure INF-10: Prevalence of markers of HBV infection estimated among national and sub-national samples of injecting drug users 2003 to 2004, where data are available – Part (i) Percentage positive for ever infected (aHBc) and current infection (HBsAg)

Figure INF-10: Prevalence of markers of HBV infection estimated among national and sub-national samples of injecting drug users 2003 to 2004, where data are available – Part (ii) Percentage positive for aHBc (ever infected) – map of EU

Figure INF-10: Prevalence of markers of HBV infection estimated among national and sub-national samples of injecting drug users 2003 to 2004, where data are available – Part (iii) Percentage positive for HBsAg (current infection) – map of EU

Figure INF-11: Trends in prevalence of markers of HBV infection estimated from national and sub-national samples of injecting drug users 1995 to 2004, where data are available – Part (i) Injecting drug users aHBc positive (ever infected)

Figure INF-11: Trends in prevalence of markers of HBV infection estimated from national and sub-national samples of injecting drug users 1995 to 2004, where data are available – Part (ii) Injecting drug users HBsAg positive (current infection)

Figure INF-12: Notified cases of hepatitis B in injecting drug users, EU countries where data are available – Part (i) Proportion injecting drug users among hepatitis B notifications with risk factor information, 2000 to 2004

Figure INF-12: Notified cases of hepatitis B in injecting drug users, EU countries where data are available – Part (ii) Indexed trend for numbers of hepatitis B notifications related to injecting drug use, 1995 to 2004

Figure INF-13: Estimated HIV, HCV and HBV prevalence among injecting drug users – studies with national and sub-national coverage. Summary of all available data across EU Member States, candidate countries and Norway, 2000 to 2004

Figure INF-14: Newly diagnosed HIV infections and HAART coverage in the WHO European region – Part (i) HIV cases under age 25 as percentage of all HIV cases

Figure INF-14: Newly diagnosed HIV infections and HAART coverage in the WHO European region – Part (ii) IDU as percentage of all HIV cases

Figure INF-14: Newly diagnosed HIV infections and HAART coverage in the WHO European region – Part (iii) HAART coverage by 3/2003

Figure INF-14: Newly diagnosed HIV infections and HAART coverage in the WHO European region – Part (iv) HAART coverage by 1/2006

---